Drug Pricing Regulator Sends Notices To 165 Firms For Overcharging
.jpg?downsize=1010:568 "Drug Pricing Regulator Sends Notices To 165 Firms For Overcharging")
India's drug pricing regulator has sent preliminary notices to 165 pharmaceutical companies for charging more than the price ceilings fixed by it.
Sun Pharmaceuticals Ltd., Abbott Healthcare Pvt. Ltd., Alkem Laboratories Ltd., Biocon Ltd., Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Glaxosmithkline Pharmaceuticals Ltd., Indoco Remedies Ltd., Lupin Ltd., Natco Pharma Ltd. and Novartis India Ltd. are among the companies found breaching the price caps.
The National Pharmaceutical Pricing Authority found 613 cases of suspected non-compliance of notified ceiling prices, based on pricing data as of January 2017, the notices issued on Friday said. The NPPA's previous list in February had listed 634 such cases.
The NPPA has fixed price ceilings for 680 medicines listed under the revised Schedule I of the Drug (Prices Control) Order, 2013.
Separately, the Department of Pharmaceuticals also notified that it has constituted a committee to review the scope of Drug (Prices Control) Order, 2013 to suggest ways to strengthen the regulatory provisions. The committee will also recommend ways for quicker implementation of the government's drug pricing policy and bring transparency to reduce litigation and review petitions.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
